Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PAINCHEK LTD Capital/Financing Update 2015

Dec 8, 2015

65534_rns_2015-12-08_99b8501f-e579-4637-a67b-99282546b109.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

MinQuest Limited

ABN

21 146 035 127

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1
+Class of+securities issued or to be
issued
2
Number of+securities issued or to be
issued (if known) or maximum number
which may be issued
Fully paid ordinary shares
22,628,048 fully paid ordinary shares issued in
accordance with the terms of the Oresearch
Acquisition
as
described
in
Section
6
(“Success Fee shares”)
  • 3 Principal terms of the[+] securities (e.g. if Fully paid ordinary shares issued on the same options, exercise price and expiry date; terms as fully paid ordinary shares except that if partly paid[+] securities, the amount the Success Fee Shares are to be held in outstanding and due dates for payment; escrow until 6 June 2016.

  • if[+] convertible securities, the conversion price and dates for conversion)

  • See chapter 19 for defined terms.

Appendix 3B Page 1

04/03/2013

4
Do the +securities rank equally
in all respects from the +issue
date with an existing +class of
quoted +securities?
If the additional +securities do
not rank equally, please state:
• the date from which they do
• the extent to which they
participate
for
the
next
dividend, (in the case of a
trust, distribution) or interest
payment
• the extent to which they do
not rank equally, other than
in
relation
to
the
next
dividend,
distribution
or
interest payment
5
Issue price or consideration
6
Purpose of the issue
(If issued as consideration for the
acquisition
of
assets,
clearly
identify those assets)
6a
Is the entity an+eligible entity
that has obtained security holder
approval under rule 7.1A?
If Yes, complete sections 6b – 6h
in relation to the+securities the
subject of this Appendix 3B, and
comply with section 6i
6b
The date the security holder
resolution under rule 7.1A was
passed
Yes, subject to the trading restrictions described in Item 3.
$0.02 per share.
Shares are issued pursuant to the Oresearch Acquisition
Agreement as approved by shareholders at the Annual General
Meeting held on 30 November 2015. The shares are to be held
in voluntary escrow until 6 June 2016.
Under the terms of the Oresearch Acquisition Agreement, the
Company agreed to pay a success fee (to be paid in Shares) to
the former shareholders of Oresearch (Oresearch Shareholders)
if any or all of them were successful in securing an interest in an
additional project for the Company within six (6) months of the
Settlement Date of the Oresearch Acquisition (Success Fee).
On 17 March 2015, the Company announced that it had entered
into a farm-in joint venture agreement (with effect on 26
February 2015) with Golden Predator Mining Corp. (Golden
Predator) pursuant to which MinQuest acquired rights to earn up
to a 75% interest in the Marg Project located in the central part
of the Yukon Territory, Canada (Marg Agreement). By entering
into the Marg Agreement the Company triggered the conditions
for the payment of the Success Fee.
Yes
30 November 2015
6c
Number of
+securities issued
without security holder approval
under rule 7.1
6d
Number of
+securities issued
with security holder approval
under rule 7.1A
6e
Number of
+securities issued
with security holder approval
under rule 7.3, or another specific
security holder approval (specify
date of meeting)
6f
Number of
+securities issued
under an exception in rule 7.2
6g
If+securities issued under rule
7.1A, was issue price at least 75%
of 15 day VWAP as calculated
under rule 7.1A.3? Include the
+issue date and both values.
Include the source of the VWAP
calculation.
6h
If+securities were issued under
rule
7.1A
for
non-cash
consideration,
state
date
on
which valuation of consideration
was released to ASX Market
Announcements
6i
Calculate the entity’s remaining
issue capacity under rule 7.1 and
rule 7.1A – complete Annexure 1
and release to ASX Market
Announcements
7
+Issue dates
Note: The issue date may be prescribed by ASX
(refer to the definition of issue date in rule
19.12). For example, the issue date for a pro rata
entitlement issue must comply with the
applicable timetable in Appendix 7A.
Cross reference: item 33 of Appendix 3B.
Nil
Nil
22,628,048 fully paid ordinary shares in accordance with
shareholder approval received at the Annual General
Meeting held on 30 November 2015.
Nil

N/a
N/a
LR7.1
35,907,210
LR7.1A
23,938,139
8 December 2015
  • See chapter 19 for defined terms.

Appendix 3B Page 3

04/03/2013

8
Number
and
+class
of
all
+securities
quoted
on
ASX
(including
the
+securities
in
section 2 if applicable)
Number +Class
206,753,351
10,000,000
22,628,048
72,816,669
Fully paid ordinary shares
Fully paid ordinary shares issued
under the Oresearch Acquisition
Agreement and subject to trading
restrictions until 5 May 2016.
Fully paid ordinary shares issued
under the Oresearch Acquisition
Agreement and subject to trading
restrictions until 6 June 2016.
Share options with an exercise price
of $0.045 per share expiring 11/05/2017
9
Number
and
+class
of
all
+securities not quoted on ASX
(including
the
+securities
in
section 2 if applicable)
Number +Class
7,923,097
6,000,000
1,696,756
1
1
Share options with an exercise
price of $0.045 per share expiring
11/02/2017
Share options with an exercise
price of $0.045 per share expiring
23/07/2017
Share options with an exercise
price of $0.10 per share expiring 10
August 2018.
Convertible note with a face value
of US$109,000 and an expiry date
of 10 August 2017 that may be
converted into equity securities at a
conversion price that is the lesser of
(a) the 5 day VWAP prior to the
issue of a conversion notice or (b)
A$0.05 per share.
Convertible note with a face value
of US$69,000 and an expiry date of
25 November 2017 that may be
converted into equity securities at a
conversion price that is the lesser of
(a) the lowest VWAP in the 5 days
prior to the issue of a conversion
notice or (b) A$0.05 per share.

10 Dividend policy (in the case of a All fully paid ordinary shares rank equally in relation to trust, distribution policy) on the dividends. increased capital (interests)

Part 2 - Pro rata issue

art 2 - Pro rata issue
11
Is
security
holder
approval
required?
12
Is the issue renounceable or non-
renounceable?
13
Ratio in which the+securities will
be offered
14
+Class of+securities to which the
offer relates
15
+Record
date
to
determine
entitlements
16
Will holdings on different registers
(or subregisters) be aggregated for
calculating entitlements?
17
Policy for deciding entitlements in
relation to fractions
18
Names of countries in which the
entity has security holders who
will
not
be
sent
new
offer
documents
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7.
19
Closing
date
for
receipt
of
acceptances or renunciations
20
Names of any underwriters
21
Amount of any underwriting fee
or commission
22
Names of any brokers to the issue
23
Fee or commission payable to the
broker to the issue
24
Amount of any handling fee
payable to brokers who lodge
acceptances or renunciations on
behalf of security holders
N/a
N/a
N/a
N/a
N/a
N/a
N/a
N/a
N/a
N/a
N/a
N/a
N/a
N/a
  • See chapter 19 for defined terms.

Appendix 3B Page 5

04/03/2013

25
If the issue is contingent on
security holders’ approval, the
date of the meeting
26
Date entitlement and acceptance
form and offer documents will be
sent to persons entitled
27
If the entity has issued options,
and the terms entitle option
holders to participate on exercise,
the date on which notices will be
sent to option holders
28
Date rights trading will begin (if
applicable)
29
Date rights trading will end (if
applicable)
30
How do security holders sell their
entitlements_in full_through a
broker?
31
How do security holders sell_part_
of their entitlements through a
broker and accept for the balance?
32
How do security holders dispose of
their entitlements (except by sale
through a broker)?
33
+Issue date
N/a
N/a
N/a
N/a
N/a
N/a
N/a
N/a
N/a

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of[+] securities ( tick one ) (a) +Securities described in Part 1

(b)[All other ][+][securities ] Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

  • 35 If the[+] securities are[+] equity securities, the names of the 20 largest holders of the additional[+] securities, and the number and percentage of additional[+] securities held by those holders

36 If the[+] securities are[+] equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

37 A copy of any trust deed for the additional[+] securities

Entities that have ticked box 34(b)

38 Number of[+] securities for which N/a +quotation is sought 39 +Class of +securities for which N/a quotation is sought 40 Do the[+] securities rank equally in N/a all respects from the[+] issue date with an existing[+] class of quoted +securities? If the additional[+] securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

  • See chapter 19 for defined terms.

Appendix 3B Page 7

04/03/2013

41 Reason for request for quotation N/a now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another[+] security, clearly identify that other[+] security)

Number +Class 42 Number and[+] class of all[+] securities N/a N/a quoted on ASX ( including the +securities in clause 38)

Quotation agreement

  • 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

  • 2 We warrant the following to ASX.

  • The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

  • There is no reason why those[+] securities should not be granted +quotation.

  • An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

    • Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  • Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the[+] securities be quoted.

  • If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

  • 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

  • 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

==> picture [124 x 45] intentionally omitted <==

Sign here: Date: 9 December 2015 Company secretary

Print name: Stephen Kelly

== == == == ==

  • See chapter 19 for defined terms.

Appendix 3B Page 9

04/03/2013

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

Part 1 Part 1
Rule 7.1 – Issues exceeding 15% of capital
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
Insertnumber of fully paid+ordinary
securities on issue 12 months before the
+issue date or date of agreement to issue
75,535,244
Addthe following:

Number of fully paid+ordinary securities
issued in that 12 month period under an
exception in rule 7.2

Number of fully paid+ordinary securities
issued in that 12 month period with
shareholder approval

Number of partly paid+ordinary
securities that became fully paid in that
12 month period
Note:

Include only ordinary securities here –
other classes of equity securities cannot
be added

Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed

It may be useful to set out issues of
securities on different dates as separate
line items
Nil
163,846,155
NIL
Subtractthe number of fully paid+ordinary
securities cancelled during that 12 month
period
Nil
“A” 239,381,399
Step 2: Calculate 15% of “A”
“B” 0.15
[Note: this value cannot be changed]
Multiply“A” by 0.15 35,907,210
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1
that has already been used
Insertnumber of+equity securities issued
or agreed to be issued in that 12 month
period_not counting_those issued:

Under an exception in rule 7.2

Under rule 7.1A

With security holder approval under rule
7.1 or rule 7.4
Note:

This applies to equity securities, unless
specifically excluded – not just ordinary
securities

Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed

It may be useful to set out issues of
securities on different dates as separate
line items
-
“C” Nil
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining
placement capacity under rule 7.1
“A” x 0.15
Note: number must be same as shown in
Step 2
35,907,210
Subtract“C”
Note: number must be same as shown in
Step 3
Nil
Total[“A” x 0.15] – “C” 35,907,210
[Note: this is the remaining placement
capacity under rule 7.1]
  • See chapter 19 for defined terms.

Appendix 3B Page 11

04/03/2013

Part 2

Part 2 Part 2
Rule 7.1A – Additional placement capacity for eligible entities
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
“A”
Note: number must be same as shown in
Step 1 of Part 1
239,381,399
Step 2: Calculate 10% of “A”
“D” 0.10
Note: this value cannot be changed
Multiply“A” by 0.10 23,938,139
Step 3: Calculate “E”, the amount of placement capacity under rule
7.1A that has already been used
Insertnumber of+equity securities issued
or agreed to be issued in that 12 month
period under rule 7.1A
Notes:

This applies to equity securities – not
just ordinary securities

Include here – if applicable – the
securities the subject of the Appendix
3B to which this form is annexed

Do not include equity securities issued
under rule 7.1 (they must be dealt with
in Part 1), or for which specific security
holder approval has been obtained

It may be useful to set out issues of
securities on different dates as separate
line items
Nil
“E” Nil

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A
“A” x 0.10
Note: number must be same as shown in
Step 2
23,938,139
Subtract“E”
Note: number must be same as shown in
Step 3
Nil
Total[“A” x 0.10] – “E” 23,938,139
Note: this is the remaining placement
capacity under rule 7.1A
  • See chapter 19 for defined terms.

Appendix 3B Page 13

04/03/2013